Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting
- 1 December 2015
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 72 (23) , S156-S161
Abstract
Objective The purpose of this study is to determine whether patients with a discharge diagnosis of bipolar depression were prescribed medications that are in accordance with evidence-based treatment guidelines and are FDA-approved for bipolar depression. Methods A retrospective study was conducted to assess prescribing of evidence-based therapies for patients discharged between November 2007 and August 2010 with a diagnosis code of BPD at the time of discharge. The primary objective of the study was to determine if evidence-based medications were prescribed at the time of discharge. Secondary objectives included analysis of other medications used, concomitant disease states and drug therapy, rate of readmission, and rate of therapeutic drug monitoring. Results Of 294 patients, 170 (58%) were prescribed evidence-based medications upon discharge. The most commonly used medication was quetiapine. The most commonly prescribed off-label medications were atypical antipsychotics. For patients on antipsychotics, rates of appropriate monitoring were variable. Seventy percent of patients receiving lithium had a therapeutic concentration prior to discharge. Differences in rates of readmission between groups were not significant. Conclusions Rates of prescribing evidence-based medications at discharge for patients with BPD were low. Additionally, evidence-based monitoring for specific medications was variable. Future studies reviewing treatment course and illness severity may provide more information about appropriate medication use in patients with BPD.Keywords
This publication has 12 references indexed in Scilit:
- Pharmaceutical treatment of acute bipolar depressionF1000 Medicine Reports, 2010
- Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysisJournal of Affective Disorders, 2010
- A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I)The Journal of Clinical Psychiatry, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and DiabetesDiabetes Care, 2009
- Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trialsThe British Journal of Psychiatry, 2009
- A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II DepressionAmerican Journal of Psychiatry, 2005
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I DepressionArchives of General Psychiatry, 2003
- Carbamazepine in manic-depressive illness: a new treatmentAmerican Journal of Psychiatry, 1980